The Respiratory Syncytial Virus Market Size in the 7MM was observed to be ~USD 1,200 million in 2022

March 04 17:46 2024
The Respiratory Syncytial Virus Market Size in the 7MM was observed to be ~USD 1,200 million in 2022

The Respiratory Syncytial Virus market report provides current treatment practices, Respiratory Syncytial Virus emerging drugs, market share of individual therapies, and current and forecasted Respiratory Syncytial Virus market size from 2019 to 2032, segmented by seven major markets. The report also covers current Respiratory Syncytial Virus treatment practices/algorithms and Respiratory Syncytial Virus unmet needs to curate the best of the opportunities and assess the underlying potential of the market.

 

Key Takeaways from the Respiratory Syncytial Virus Market Research Report

  • The Respiratory Syncytial Virus market is expected to grow due to factors like increase in the patient pool and expected entry of emerging therapies.
  • In 2022, the total incident cases of Respiratory Syncytial Virus in the 7MM were ~8,495,000, and these cases are anticipated to increase during the study period.
  • Total incident cases of Respiratory Syncytial Virus were highest in those below 5 years, followed by 65 years and above, and the least number of cases were found in the 5 to 64 years age group.
  • The leading Respiratory Syncytial Virus Companies working in the market include Bavarian Nordic, GlaxoSmithKline, Janssen, Sanofi, AstraZeneca, Moderna, ReViral, Pfizer, and others.
  • Promising Respiratory Syncytial Virus Pipeline Therapies include Nirsevimab, RSVpreF, RSVPreF3 Vaccine, MVA-BN-RSV Vaccine, Ad26.RSV.preF, mRNA-1345, and others.

 

Discover which therapies are expected to grab the major respiratory syncytial virus market share @ Respiratory Syncytial Virus Market Report

 

Respiratory Syncytial Virus Overview

Respiratory syncytial virus (RSV) is a common respiratory virus that infects the nose, throat, lungs, and breathing passages. RSV belongs to the genus Orthopneumo virus within the family Pneumoviridae and order Mononegavirales. Members of this genus include human RSV, bovine RSV, and murine pneumonia virus. Two major antigenic subtypes of human RSV (A and B) are determined mainly by antigenic drift and duplications in RSV-G sequences but accompanied by genome-wide sequence divergence, including within RSV-F.

 

Respiratory Syncytial Virus Epidemiology Segmentation in the 7MM

  • Total Respiratory syncytial virus Incident Cases
  • Respiratory syncytial virus Age-specific Incident Cases

 

Download the report to understand which factors are driving respiratory syncytial virus epidemiology trends @ Respiratory Syncytial Virus Epidemiological Insights

 

Respiratory Syncytial Virus Treatment Market

Respiratory Syncytial Virus treatment is currently limited to supportive care and prophylactic antibody use. It may includehydration, supplemental oxygen, suctioning of airways, and mechanical ventilation when needed.

Bronchodilators such as albuterol have long been used and studied in RSV bronchiolitis. Unfortunately, there is noclear consensus as to their effectiveness. Although extensive research has gone into studying the effect ofbronchodilators in young infants and children, very limited studies or recommendations are available for adultpatients with RSV infection.

Because adults with RSV lower respiratory infections often have co-infections andmultiple comorbidities, it is much harder to develop a guideline that applies to such a heterogeneous population.Nebulized 3% saline solution has also been studied as a treatment for RSV bronchiolitis. Although there may be a rolefor nebulized hypertonic saline in the inpatient setting, its acute use in the ED appeared to be limited in the currentstudies. In the case of corticosteroids, there was no statistically significant benefit on hospital stay or clinicaloutcomes with the use of corticosteroids compared with placebo.

 

Respiratory Syncytial Virus Drugs Uptake

Nirsevimab is an immunization that provides direct prophylactic RSV protection to all infants via an antibody to help prevent LRTI caused by RSV. Monoclonal antibodies do not require the activation of the immune system to help offer rapid and direct protection against disease. With nirsevimab, the goal is to provide rapid and direct protection to the infant through a single immunization. It is the first potential immunization to show protection against RSV in infants in a Phase III trial. Currently, the drug is being studied in Phase III. Regulatory submissions have begun in the first half of 2022. Recently in September 2022, CHMP recommended approval of BEYFORTUS (nirsevimab) for the prevention of RSV disease in infants in Europe. The company plans US submission by the second half of 2022.

 

Pfizer’s investigational RSV vaccine candidate, RSVpreF, builds on foundational basic science discoveries, including those made at the National Institutes of Health (NIH), which detailed the crystal structure of prefusion F, a key form of the viral fusion protein (F) that RSV uses to attack human cells. The NIH research showed that antibodies specific to the prefusion form were highly effective at blocking virus infection, suggesting a prefusion F-based vaccine may confer optimal protection against RSV. After this important discovery, Pfizer tested numerous versions of the viral protein and identified those that elicited a strong antiviral immune response in preclinical evaluation. The vaccine candidate comprises two preF proteins selected to optimize protection against RSV A and B. Currently, the company is investigating this vaccine in many Phase III clinical trials.

 

RSVpreF 3 contains a recombinant subunit pre-fusion RSV antigen combined with GSK’s proprietary AS01 adjuvant, which is also used in the company’s shingles vaccine. The antigen plus adjuvant combination may help overcome the natural age-related decline in immunity that contributes to the challenge of protecting older adults from RSV disease.

 

To know more about respiratory syncytial virus guidelines, visit @ Respiratory Syncytial Virus Treatment Market

 

Respiratory Syncytial Virus Market Dynamics

The respiratory syncytial virus market is expected to grow due to factors like increase in the patient pool and expected entry of emerging therapies. While no RSV vaccine is currently available; however, many promising vaccine candidates are in clinical trials, which will be in the respiratory syncytial virus market soon. A safe and effective vaccine could save many lives and reduce hospitalizations significantly.

 

Respiratory Syncytial Virus Pipeline Therapies and Key Companies

  • MVA-BN-RSV Vaccine: Bavarian Nordic
  • RSVpreF (PF-06928316): Pfizer
  • RSVPreF3 (GSK3844766A) Vaccine: GlaxoSmithKline
  • VAC 18193 (Ad26.RSV.preF): Janssen
  • MEDI8897 (nirsevimab): Sanofi/AstraZeneca
  • mRNA-1345: Moderna
  • RV521/PF-07923568 (Sisunatovir): ReViral/Pfizer

 

Learn more about the FDA-approved respiratory syncytial virus drugs @ Drugs for Respiratory Syncytial Virus Treatment

 

Scope of the Respiratory Syncytial Virus Market Research Report

  • Coverage- 7MM
  • Study Period- 2019-2032
  • Respiratory Syncytial Virus Companies- Bavarian Nordic, GlaxoSmithKline, Janssen, Sanofi, AstraZeneca, Moderna, ReViral, Pfizer, and others.
  • Respiratory Syncytial Virus Pipeline Therapies- Nirsevimab, RSVpreF, RSVPreF3 Vaccine, MVA-BN-RSV Vaccine, Ad26.RSV.preF, mRNA-1345, and others.
  • Respiratory Syncytial Virus Market Dynamics: Respiratory Syncytial Virus Market Drivers and Barriers
  • Respiratory Syncytial Virus Market Access and Reimbursement, Unmet Needs

 

Discover more about respiratory syncytial virus drugs in development @ Respiratory Syncytial Virus Clinical Trials

 

Table of Content

1. Key Insights

2. Report Introduction

3. Respiratory Syncytial Virus (RSV) Market Overview at a Glance

4. Executive Summary of Respiratory Syncytial Virus (RSV)

5. Key Events

6. Disease Background and Overview

7. Treatment and Management

8. Methodology

9. Epidemiology and Patient Population

10. Patient Journey

11. Marketed Products

12. Emerging Therapies

13. Respiratory Syncytial Virus (RSV) Seven Major Market Analysis

14. Market Access and Reimbursement

15. RSV Reimbursement

16. KOL Views

17. Unmet Needs

18. SWOT Analysis

19. Appendix

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

view more articles

About Article Author